CA2981191C - Compositions comprising pregnancy specific glycoproteins and methods of use thereof - Google Patents

Compositions comprising pregnancy specific glycoproteins and methods of use thereof Download PDF

Info

Publication number
CA2981191C
CA2981191C CA2981191A CA2981191A CA2981191C CA 2981191 C CA2981191 C CA 2981191C CA 2981191 A CA2981191 A CA 2981191A CA 2981191 A CA2981191 A CA 2981191A CA 2981191 C CA2981191 C CA 2981191C
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
seq
peptide
psg1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2981191A
Other languages
English (en)
French (fr)
Other versions
CA2981191A1 (en
Inventor
Gabriela DVEKSLER
Harry L. Malech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
US Department of Health and Human Services
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc, US Department of Health and Human Services filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of CA2981191A1 publication Critical patent/CA2981191A1/en
Application granted granted Critical
Publication of CA2981191C publication Critical patent/CA2981191C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2981191A 2015-09-17 2016-09-16 Compositions comprising pregnancy specific glycoproteins and methods of use thereof Active CA2981191C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219900P 2015-09-17 2015-09-17
US62/219,900 2015-09-17
PCT/US2016/052131 WO2017049082A2 (en) 2015-09-17 2016-09-16 Compositions comprising pregnancy specific glycoproteins and methods of use thereof

Publications (2)

Publication Number Publication Date
CA2981191A1 CA2981191A1 (en) 2017-03-23
CA2981191C true CA2981191C (en) 2022-09-13

Family

ID=58289625

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2981191A Active CA2981191C (en) 2015-09-17 2016-09-16 Compositions comprising pregnancy specific glycoproteins and methods of use thereof

Country Status (6)

Country Link
US (2) US11007249B2 (https=)
EP (1) EP3261722B1 (https=)
JP (1) JP2018529625A (https=)
AU (1) AU2016323769B2 (https=)
CA (1) CA2981191C (https=)
WO (1) WO2017049082A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024514195A (ja) 2021-04-14 2024-03-28 ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク 脳血管イベントおよび神経障害の治療
US20240197827A1 (en) * 2021-04-14 2024-06-20 University College Cork - National University Of Ireland, Cork Psg1 for use in the treatment of osteoarthritis
CN120379687A (zh) 2022-10-14 2025-07-25 爱尔兰国立科克大学 胎盘表达的蛋白用于治疗肌腱损伤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5169835A (en) 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2006503110A (ja) * 2002-10-09 2006-01-26 トーラーレックス， インク． エフェクタｔ細胞または制御性ｔ細胞に選択的に結合する分子およびその使用方法
CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection

Also Published As

Publication number Publication date
JP2018529625A (ja) 2018-10-11
USRE50535E1 (en) 2025-08-19
AU2016323769B2 (en) 2022-05-26
US11007249B2 (en) 2021-05-18
EP3261722A4 (en) 2018-11-21
CA2981191A1 (en) 2017-03-23
US20180177844A1 (en) 2018-06-28
WO2017049082A2 (en) 2017-03-23
EP3261722A2 (en) 2018-01-03
EP3261722B1 (en) 2021-04-14
AU2016323769A1 (en) 2017-10-19
WO2017049082A3 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
US12060401B2 (en) Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
KR102777151B1 (ko) 인터루킨-2의 부분 효능제
KR102653758B1 (ko) 인터류킨-2/인터류킨-2 수용체 알파 융합 단백질 및 사용 방법
CA2981191C (en) Compositions comprising pregnancy specific glycoproteins and methods of use thereof
JP2023106434A (ja) 制御性ｔ細胞エピトープ
KR20240007197A (ko) 자가면역 및 동종면역 질환의 예방 및/또는 치료를 위한 면역억제성 항원-특이적 키메릭 항원 수용체 조절 t 세포
WO2004013179A1 (en) Conjugate of notch signalling pathway modulators and their use in medical treatment
AU2020368012A1 (en) Compounds for immunomodulation
KR20220044683A (ko) 관절염 치료를 위한 hla-dr/cii 펩티드 복합체
EP3191186B1 (en) Compositions and methods of using interleukin-4 induced gene 1 (il4i1)
EP2931293B1 (en) Compositions and methods for regulating erythropoiesis
WO2001002003A1 (en) Method of treating psoriasis with il-15 antagonist
JP4989850B2 (ja) ＴＧＦ−βの遮断により腫瘍再発を防ぐ方法
EP2032601B1 (en) Peptides regulating the surface expression of the t cell receptor
KR101739305B1 (ko) 릴랙신을 유효성분으로 포함하는 항원 제시 세포의 성숙화 유도용 조성물
WO1998056819A1 (en) Methods of regulating t cell and macrophage cytokine production, function and pathogenicity
US20070041937A1 (en) G-csf derivative for inducing immunological tolerance

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210719

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240906

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240906

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240906

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250912

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250912